Brief: Poxel: latest clinical studies backed efficacy for its PXL770 product

Poxel SA

25/06/2021 13:03

June 25 (Reuters) - Poxel SA  POXEL.PA :
    
    * Poxel Presents Results of Two Clinical Studies on its
Direct AMP Kinase Activator, the PXL770, at the International
Liver Congress (ILC)™ 2021 Pr. Kenneth Cusi presented the
results of the STAMP-NAFLD 12-week, randomized, controlled Phase
2a trial of PXL770 in 120 presumed NASH patients – selected as a
“Best of ILC” abstract Pr. Vlad Ratziu presented the results
from a 4-week PK/PD target engagement study of PXL770
    
    * RESULTS OF THESE LATEST TWO CLINICAL STUDIES PROVIDE
STRONG EVIDENCE OF EFFICACY FOR PXL770
Source text for Eikon:  ID:nBw5QbXXNa 
Further company coverage:  POXEL.PA 

 (Reporting by Sudip Kar-Gupta)
 ((sudip.kargupta@thomsonreuters.com;))